Mythili Koneru

Senior Vice President, Clinical Development
Marker Therapeutics
Philipp Nold
Mythili Koneru, M.D., Ph.D. is Senior Vice President of Clinical Development at Marker Therapeutics, a clinical-stage company specializing in the development of T cell-based immunotherapies for treatment of hematological malignancies and solid tumors. In this role, she is responsible for clinical development strategy, clinical study design, and medical oversight of the Company's therapeutic product candidates. Dr. Koneru joins Marker Therapeutics from Eli Lilly and Company, where she served most recently as Associate Vice President of Immuno-Oncology. In her previous role, Dr. Koneru designed early-stage clinical trials for hematologic and solid tumor malignancies and was instrumental in developing clinical trial protocols, serving as medical lead for trial conduct. Prior to Eli Lilly, Dr. Koneru completed her oncology fellowship in the laboratory of Dr. Renier Brentjens at Memorial Sloan-Kettering Cancer Center, where she developed adoptive T cell therapies in both leukemia and solid tumor malignancies in early phase clinical trials.


October 29 2019, 14:20
 - 14:50
Multi-Tumor-Associated Antigen-Specific (MultiTAA) T Cells As A Bridge For Both Hematological Malignancies And Solid Tumors